Department of Hepatology and Transplant Hepatology, Institute of Liver Diseases and Transplantation, Gleneagles Global Health City, Chennai 600 100, India.
Department of Transfusion Medicine, Gleneagles Global Health City, Chennai 600 100, India.
Indian J Gastroenterol. 2020 Dec;39(6):544-549. doi: 10.1007/s12664-020-01095-y. Epub 2021 Jan 6.
Therapeutic plasma exchange (TPE) has been utilized in various liver disorders. There is limited data on the efficacy of TPE in patients with acute liver failure (ALF).
Study group consisted of patients who underwent TPE for ALF due to yellow phosphorous poisoning (YPP) between 2015 and 2019. Demographic data and biochemical parameters were recorded before and after TPE. Overall survival and transplant-free survival (based on King's College Hospital Criteria [KCHC]) were analyzed.
Forty-three patients underwent TPE for ALF due to YPP. Most of them were young males. Overall survival was 34 (79.06%). In our study population, 20 patients fulfilled KCHC (Group A) and 23 did not fulfill KCHC (Group B). Both the groups showed significant improvement in alanine aminotransferase, aspartate aminotransferase, and international normalized ratio (INR) after TPE (p < 0.05). In Group B, there was significant improvement in ammonia after TPE (p < 0.05) and all 23 patients (100%) survived after TPE. In Group A, 4 underwent liver transplantation (LT), 7 survived without LT, and the remaining 9 died without LT. Mean survival after completing TPE was 41.2 ± 44.5 days in Group A and 90 days in Group B. This difference was statistically significant (p = 0.001). There was statistically significant difference in post-TPE values of INR (p = 0.012) and ammonia (p = 0.011) between non-survivors and survivors. Adverse events such as hypotension (11.62%) and minor allergic reaction (4.65%) were managed conservatively.
TPE is an effective procedure in ALF due to YPP, not fulfilling KCHC for LT. In KCHC fulfilled group, though it shows LT-free survival benefit, there is requirement of prospective, large volume, multi-center study to assess its efficacy.
治疗性血浆置换(TPE)已应用于多种肝脏疾病。关于 TPE 在急性肝衰竭(ALF)患者中的疗效,数据有限。
研究组由 2015 年至 2019 年间因黄磷中毒(YPP)行 TPE 治疗的 ALF 患者组成。记录 TPE 前后的人口统计学数据和生化参数。分析总生存率和无移植生存率(基于 King's College Hospital 标准[KCHC])。
43 例 YPP 所致 ALF 患者行 TPE 治疗。他们大多数是年轻男性。总生存率为 34(79.06%)。在我们的研究人群中,20 例符合 KCHC(A 组),23 例不符合 KCHC(B 组)。两组 TPE 后丙氨酸氨基转移酶、天冬氨酸氨基转移酶和国际标准化比值(INR)均显著改善(p<0.05)。B 组 TPE 后血氨显著改善(p<0.05),23 例患者均存活。A 组中有 4 例接受了肝移植(LT),7 例无 LT 存活,其余 9 例无 LT 死亡。A 组完成 TPE 后的平均存活时间为 41.2±44.5 天,B 组为 90 天。差异有统计学意义(p=0.001)。非幸存者与幸存者 TPE 后 INR(p=0.012)和血氨(p=0.011)值差异有统计学意义。低血压(11.62%)和轻度过敏反应(4.65%)等不良事件经保守治疗后得到控制。
TPE 是一种有效的 YPP 所致 ALF 治疗方法,不符合 LT 的 KCHC。在符合 KCHC 的组中,尽管它显示出 LT 无生存获益,但仍需要进行前瞻性、大样本、多中心研究来评估其疗效。